Indian AI startup Graph AI, focused on automating pharmacovigilance for the pharmaceutical sector, has raised $13.3 million in a Series A round. The capital infusion, led by Insight Partners with participation from Bessemer Venture Partners, will fund its international expansion across the US and European markets.
- Raised $13.3 Mn Series A led by Insight Partners
- Focus on global expansion in US and Europe
- Offers AI-driven pharmacovigilance SaaS platform
What happened
Graph AI, an India-based AI startup specializing in pharmaceutical safety solutions, closed a $13.3 million Series A funding round. Insight Partners led the round, with follow-on investment from existing backer Bessemer Venture Partners. The fresh capital will support Graph AI’s plans to expand operations beyond India into the United States and Europe, accelerating the adoption of its AI-powered platform.
Since its founding in 2024 and seed round in late 2025, Graph AI has launched two AI modules: /intake for adverse event data triage and /nucleus for end-to-end case processing automation. A third module, /report, designed for automated aggregate safety reporting, is scheduled to launch shortly. These developments reinforce the company’s aim to streamline and automate pharmacovigilance workflows for pharmaceutical and biotech customers worldwide.
Why it matters
Pharmacovigilance, the continuous monitoring and reporting of adverse drug events, is critical to drug safety regulation and patient protection. Graph AI’s product suite automates these complex processes, improving efficiencies while ensuring compliance with global regulatory mandates. By bringing AI-driven automation to this traditionally manual and services-heavy field, the startup addresses a vital market need.
The funding round signals increasing investor confidence in AI applications within the pharmaceutical sector, reflecting broader trends of AI adoption in drug discovery and safety monitoring. With rivals and complementary startups also securing significant investments, Graph AI’s growth exemplifies the rising importance of AI in transforming healthcare and life sciences industries.
What to watch next
Attention will focus on Graph AI’s ability to execute its international expansion strategy and secure new enterprise customers in the US and European markets, which have stringent regulatory environments. Successful deployment of its upcoming /report module and future development of advanced safety analytics tools will be critical to maintaining competitive differentiation and scaling revenue.
Additionally, observing the startup’s collaborations and partnerships for signal detection and risk management will be important, as these features underpin the value proposition for pharmaceutical clients. The broader AI funding landscape in India and global pharma will also influence Graph AI’s growth trajectory, alongside advancements in AI regulatory acceptance across jurisdictions.